Endo International plc / Auxilium Pharmaceuticals, Inc.
2014 · Acquisition/Merger · $2.6B · Complete
Announcement Sentiment
88
Strongly positive
Endo agreed to acquire specialty biopharma Auxilium Pharmaceuticals for $33.25 per share (cash-and-stock) in a deal valued at $2.6B including assumed debt. Auxilium simultaneously terminated its earlier QLT reverse-merger agreement, paying QLT a $28.4M break fee. Closed January 29, 2015.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Impaired/Written Down
Pipeline outcome
Mixed
Assessment window: 10yr post-close.
Key facts
AnnouncedOct 09, 2014
ClosedJan 29, 2015
Deal value$2.6B
Deal typeAcquisition/Merger
Therapeutic areaPeyronie's disease, Dupuytren's contracture, men's health
IndicationsPeyronie's disease, Dupuytren's contracture, men's health